Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKromek Regulatory News (KMK)

Share Price Information for Kromek (KMK)

Share Price is delayed by 15 minutes
Get Live Data
8.60    -0.35 (-4.00%)
Bid:
8.20
Ask:
9.00
Spread: 0.80 (9.756%)
Market Cap: £55.03m
KMK Live PriceLast checked at - London Stock Exchange

Intraday Kromek Share Chart

Bottle Scanner Orders and New Accreditation

27 Nov 2013 07:00

RNS Number : 0120U
Kromek Group PLC
27 November 2013
 



 

Kromek Group plc

("Kromek" or "the Company")

Bottle Scanner Orders and New Accreditation

 

Kromek, a supplier of patented radiation detection technologies to the medical, security and nuclear markets, announces that it has secured a number of orders from UK and European airports for its ECAC (European Civil Aviation Conference) certified Bottle Scanner, which screens passengers' liquid containers for explosives, affording them a quicker and safer passage through security.

As well as receiving orders from nine UK Airports, new orders have been secured to supply airports in Portugal, Cyprus, and Belgium, with negotiations ongoing with other airports in the UK and Europe. The Company has already delivered bottle scanners to a number of the UK airports and these additional units mean that the majority of Kromek's Bottle Scanner sales targets for the current financial year are now either delivered or contracted for delivery in the year to 30 April 2014.

These latest orders build on the presence of Kromek's Bottle Scanners, which have also been sold into airports in Finland, Germany and Australia.

These orders coincide with the phase 1 implementation of a 3 phase International Civil Aviation Organization pathway, mandated in the EU, from January 2014 to January 2016. Phase 1 will initially mandate that all EU airports provide the security screening equipment needed to allow the passage of liquids through airports for connecting passengers. Ultimately, travel restrictions will be relaxed on the passage of all liquids, aerosols and gels by the end of phase 3.

In addition, the Company is pleased to announce that it has received a new certification from the ECAC for an improved Bottle Scanner, which reduces the previous scanning time by half, now allowing the screening process to be completed in just over ten seconds and still retaining the highest performance category in its class.

Commenting on the announcement, Arnab Basu, CEO of Kromek, commented: "We are pleased to announce more progress in the security screening area of our business. We believe that the take-up of our technology by numerous airports across the EU is an excellent validation of our offering. The Bottle Scanner provides one of the simplest ways to scan liquid in sealed containers. Our product can scan and identify liquids in all types of containers without any input from the operator, opening or damaging the products, and provides a simple pass or fail answer.

"The accreditation for our new, shorter-cycle Bottle Scanner from ECAC proves the efficacy of our technology and also shows that we are continually working with our targeted customer base to improve our system and the quality of the user experience."

-ends-

 

For further information, please contact:

Kromek Plc

Arnab Basu, CEO

Derek Bulmer, CFO

 

Tel: 01740 626060

Panmure Gordon

As Nominated Adviser and Broker

Corporate Finance

Freddy Crossley/ Grishma Patel

Broking

Adam Pollock/ Charlie Leigh-Pemberton

 

Tel: 020 7886 2500

Tavistock Communications

Matt Ridsdale

Andrew Dunn

Tel: 020 7920 3150

 

About Kromek

Kromek Group plc is a UK technology company (global HQ in County Durham) and a leading developer of high performance radiation detection products based on cadmium zinc telluride ("CZT"). Using its core CZT technology Kromek designs, develops and produces x-ray and gamma ray imaging and radiation detection products for the medical, security screening and nuclear markets.

The Group's products provide high resolution information on material composition and structure and are used in multiple applications, ranging from the identification of cancerous tissues to hazardous materials, such as explosives, and the analysis of radioactive materials.

Kromek uses multiple technologies in its manufacturing processes, including the established methods of 'liquid phase' detector production, and also 'vapour phase' production methods, which allow the production of high quality, high performance detectors on an industrial scale. Kromek has an intellectual property portfolio of more than 70 granted patents and 110 pending applications.

The Group's business model provides a vertically integrated technology offering to customers, from the growth of CZT crystals to finished products or detectors, including software, electronics and application specific integrated circuits ("ASICs").

The Board believes that the vertical integration offered by Kromek, combined with the benefit of 25 years of research into CZT production and the patents and trade secrets accumulated by the Group, are unparalleled in the market place.

The Group has operations in the UK, Germany and US (California and Pennsylvania), and is selling internationally through a combination of distributors and direct OEM sales.

Currently, the Group has over a hundred full time employees across its global operations.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEAXFKASNDFFF
Date   Source Headline
4th Jun 20267:00 amRNSGrant of Long-Term Incentives
2nd Jun 20267:00 amRNS-RLaunch of new interactive investor hub
1st Jun 20267:00 amRNSPDMR/Director Shareholding, Issue of Equity & TVR
12th May 20267:00 amRNSFull Year 2026 Trading Update
30th Apr 20262:30 pmRNSIssue of Equity, TVR & Extension of Options
9th Mar 20261:36 pmRNSDirector Share Purchase
9th Mar 20261:36 pmRNSDirector Share Purchase
20th Jan 20267:00 amRNSInterim Results
16th Dec 20257:00 amRNSNotice of Results
15th Dec 202512:27 pmRNSHolding(s) in Company
3rd Nov 202511:32 amRNSDirector Share Purchase
28th Oct 20257:00 amRNSGrant of Options, PDMR Dealings and TVR
27th Oct 20252:16 pmRNSResult of AGM
27th Oct 20257:00 amRNSPre-close Trading Statement
3rd Oct 202510:06 amRNSNotice of AGM and Publication of Annual Report
16th Sep 20257:00 amRNSFinal Results
11th Aug 20257:00 amRNSNew Biosecurity Award from UK MoD
28th Jul 20257:00 amRNS$5m received under Siemens Healthineers agreement
21st Jul 20257:00 amRNS£1.7m contract win under UK Government Framework
23rd Jun 202511:40 amRNS-RCapital Markets Day Presentation
18th Jun 20257:00 amRNSCapital Markets Day
16th Jun 20254:02 pmRNSHolding(s) in Company
9th Jun 20257:00 amRNSIssue of Equity and Total Voting Rights
3rd Jun 20251:53 pmRNSHolding(s) in Company
3rd Jun 20257:00 amRNSCapital Markets Day
28th May 20257:00 amRNSNew Nuclear Security Orders
8th May 20257:05 amRNSDirectorate Change
8th May 20257:00 amRNSFull Year 2025 Trading Update
17th Feb 20257:00 amRNS$25m received under Siemens Healthineers agreement
7th Feb 20251:49 pmRNSHolding(s) in Company
6th Feb 202512:35 pmRNSHolding(s) in Company
30th Jan 20257:01 amRNSInterim Results
30th Jan 20257:00 amRNSKromek Signs Agreements with Siemens Healthineers
13th Dec 202412:20 pmRNSResult of AGM
18th Nov 20247:00 amRNSNotice of AGM and Publication of Annual Report
28th Oct 20247:01 amRNSFinal Results and Publication of Annual Report
28th Oct 20247:00 amRNSFinancing Update
30th Sep 20247:00 amRNSUpdate on Full Year Results
23rd Sep 20247:00 amRNSKromek selected for UK Government Framework
16th Sep 20247:00 amRNSKromek awarded £2.0m contract from UK MOD
21st Aug 202410:14 amRNSHolding(s) in Company
7th Jun 20249:20 amRNSCancellation of outstanding Convertible Loan Notes
29th May 20247:00 amRNSFY 2024 Trading Update
25th Apr 20247:00 amRNSKromek receives new Nuclear Security contract
3rd Apr 20243:13 pmRNSDirector/PDMR Shareholding
26th Mar 20247:00 amRNSKromek receives $2.1m security screening order
6th Mar 20243:21 pmRNSHolding(s) in Company
4th Mar 202412:16 pmRNSHolding(s) in Company
4th Mar 202411:51 amRNSResult of General Meeting
5th Feb 202410:17 amRNSConversion of £1.5m of Convertible Loan Notes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.